These observations led to the postulate that at disease onset, the pathological effects or severity of B2m-free HCs or Proto-HLA, as they occur in autoimmune diseases and human cancers, can be minimized or eliminated by administration of HC-specific mAbs such as HC10. This evidence concerns the gene B2M and cancer.